Canada markets closed

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.3400+0.0300 (+1.30%)
At close: 04:00PM EDT
2.3900 +0.05 (+2.14%)
After hours: 07:59PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • W
    Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes (MDS)
  • K
    Novel Therapies in Development for Myelofibrosis Show Promise

     September 29, 2022
    Helen T. Chifotides, PhD, Srdan Verstovsek, MD, PhD

    During the MPN session at the 10th Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), Srdan Verstovsek, MD, PhD, United Energy Resources, Inc, Professor of Medicine and hematologist oncologist at The University of Texas MD Anderson Cancer Center, will highlight recent advancements in developing novel therapeutic strategies for MF during the Myeloproliferative Neoplasms Session on September 29, 2022.

    Lastly, imetelstat, a first-in-class potent telomerase inhibitor, yielded a median overall survival of 29.9 months (dose, 9.4 mg/kg) in patients with intermediate-2 or high-risk MF relapsed/refractory to JAK inhibitors in the phase 2 IMbark study (NCT02426086).26The overall survival benefit from imetelstat compared favorably with matched historical data for treatment with BAT after JAK inhibitor failure. The international, registrational phase 3 trial IMpactMF (NCT04576156) is underway to evaluate the potential survival advantage—an unprecedented trial end point for investigational MF therapies—of imetelstat in intermediate-2 or high-risk JAK inhibitor–refractory MF.
  • K
    Future Directions for MPN Research
    September 30, 2022
    Srdan Verstovsek, MD, PhD

    We are looking first to see whether the combinations that are exploring enhancement of the control of the sign symptoms, on top of JAK inhibitors, will actually do that well or well enough to be approved and considered everyday practice. We are also looking in the very near future to see whether any of these therapies can prolong life. Overall survival is already in 1 study with a possible approval with the drug called imetelstat, which is a telomerase inhibitor, a primary goal. This is a phase 3 randomized study in a second-line setting.
  • U
    Uncle Ballsio
    Watch, with no other factors/news, GERN will spend the 4th Qtr. of '22 going up 50% as we head towards news one way or the other in January. look for $3.50/shr. With short levels at such historic lows for the company and institutional holdings at such highs, prepare for a great upcoming run. There is a reason like today where indexes are red/GERN is green.
  • R
    In one month shorts have dropped 33% to 12 million
  • R
    Congrats to longs that didn’t get shaken out in the past week - especially with tons of fear uncertainty and doubt being spewed here.

    Who sells before the catalyst rich period,m. Sell before Jan 2023 ? As Seinfeld would say, who are these people?
  • L
  • D
    Signal Hire shows Nishan Sengupta working concurrently for Geron and J&J

    Work Experience
    Vice President-Market Access, Pricing, Evidence Strategy at Geron Corporation (Menlo Park, California, United States) Aug 2021 - Current
    Global/US Access Strategy Lead-IMBRUVICA, B-Cell, Rare Hem at Johnson & Johnson (New Brunswick, NJ, United States) Aug 2019 - Current
  • V
    wish I have few thousands extra money to buy more of these
  • A
    Yesterday the shorts shorted 66% of all GERN stock trades to drive GERN's stock price down. See it at Fintel's web site. Short sellers are buying up all the GERN stock they can today.
  • G
    Short positions down to less than 4 days to cover. Who is still selling under $3 if its not shorts?
  • t
    New Career Just Added at Geron

    New Jersey-Based Opportunities
    Associate Director, Information Technology Infrastructure

    Geron is hiring many Key Staff, DR, PHD, ........

    Something Tells PR Coming
  • C
    GERN is up 2% for the week. The Dow, Nasdaq and everything else dow for the week. Look it up.
  • t
    A good day for GERN consderingi
  • C
    GERN was a top preforming biotech today among all biotech companies.
  • A
    Instutitions have bought 15 million more GERN shares from the last report.
    Short sellers have bought 15 million GERN shares since the end of June.
    11 stock analysis are now for the first time calling GERN stock a strong buy .and a buy.
    What does this mean? Somebody thinks something epic is about to happen with GERN.
  • A
    October is here. GERN top line results are do January first after 10 years of drug trials. JNJ employees are running to GERN for employement. 11 analysis are calling GERN a buy. Our time as come!
  • A
    Monday is October 3rd and GERN will only be a few weeks away from world changing fantastic FDA phase 3 top line drug results. Think about that!
  • J
    $SLS conversation
    As sure as shorts sold 50% to hold this down today
    \walkerbill 76 27,387 reactions, is a lowlife
    30,000 posts, out of context distortion and pure fabrication on multiple boards using the same playbook. $GERN $CDXC
  • L
    The evidence is compelling. JNJ, AbbVie and Geron have been working on combinations of Imetelstat (Telomerase inhibitor) and Venetroclax (BCL-2 protein inhibitor) for a very long time, with amazing preclinical results that are now becoming clinical results (TELOMERE AML trial and JNJ successes for example). JS, Dr. Rizo and the ever-building Geron staff know that they have a winner and time is on their side. The key words are "enhances apoptosis" (kills cancer cells by two difference methods in combination).

    Note: Aleksandra Rizo's name (2017)
    Abstract 1101: Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor
    venetoclax enhances apoptosis in vitro and increases survival in vivo in acute myeloid leukemia

    Joshua J. Rusbuldt, Leopoldo Luistro, Diana Chin, Melissa Smith, Amy Wong, Margarita Romero, Aleksandra Rizo, Jacqueline Bussolari, Fei Huang and Amy (Kate) Sasser
    DOI: 10.1158/1538-7445.AM2017-1101 Published July 2017